DxNow Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • DxNow's estimated annual revenue is currently $4M per year.(i)
  • DxNow's estimated revenue per employee is $251,000

Employee Data

  • DxNow has 16 Employees.(i)
  • DxNow grew their employee count by -24% last year.

DxNow's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$18.6M7432%N/AN/A
#2
$7.8M31-9%N/AN/A
#3
$4M167%N/AN/A
#4
$4M167%N/AN/A
#5
$6M244%N/AN/A
#6
$19.1M7629%N/AN/A
#7
$7.8M1633%$10.9MN/A
#8
$5M20N/AN/AN/A
#9
$27.6M11010%N/AN/A
#10
$4M160%N/AN/A
Add Company

What Is DxNow?

Leveraging exclusively-licensed technologies developed in the Demirci Bio-Acoustic MEMS in Medicine Labs (BAMM Labs) at Brigham & Women's Hospital and Stanford University School of Medicine, DxNow, Inc. (www.dxnow.com) is developing sperm separation products to assist clinical practitioners in the selection of healthy motile sperm, with the ultimate objective of enabling improved outcomes for couples undergoing ART procedures. Our fertility products eliminate the need and standardize the process for time-consuming sample preparation and sperm-damaging centrifugation. The result is a simple and fast method, enabling the embryologist to consistently select sperm with higher motility, better morphology, lower ROS generation and lower DNA fragmentation. Founded in 2013, DxNow is a privately-held Delaware C corporation whose corporate headquarters and primary research and development labs are located in Gaithersburg, Montgomery County, Maryland. This location offers close proximity to Washington, DC, the USFDA, USPTO, NIH, CMS and other agencies relevant to DxNow's business interests, as well three major airports. Our mission is to develop and commercialize novel tools that: >Deliver improvements in assisted reproductive technology (ART) in humans and animals >Facilitate faster identification of individuals for prosecution within the criminal justice system >Enable advances in life science research and applied markets >Provide faster, more cost-effective diagnostic solutions for chronically ill patients and their caregivers

keywords:N/A

N/A

Total Funding

16

Number of Employees

$4M

Revenue (est)

-24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DxNow News

2022-04-19 - Sperm Separation System Market Is Projected to Grow ...

Lotus Bio (NYMPHAEA) Ltd., CooperSurgical Inc., Vitrolife, Cook, FUJIFILM Irvine Scientific, DxNow, memphasys, among other players domestic and global.

2022-04-06 - Infertility Treatment Devices and Equipment Market to Garner ...

Microptic; Coopersurgical, Inc; Cook Medical LLC; Dxnow; Eppendorf AG; AB Scientific Ltd; Hamilton Thorne, Inc; Rocket Medical Plc;...

2022-03-30 - Sperm Separation Systems Market is Booming with Strong Growth Prospects | Top Players: DxNow, Gennet,

... Growth Prospects | Top Players: DxNow, Gennet, IVFStore, LotusBio ... and some of the key players in the study are DxNow, Inc., Gennet,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M16-91%N/A
#2
$7.5M160%N/A
#3
$2.5M16-27%N/A
#4
$3.3M176%N/A
#5
$1.5M170%N/A